Prana Biotechnology has today announced that it has entered into a securities purchase agreement for a lead investment by Boston based Life Biosciences LLC (“Life Biosciences”) to raise up to approximately A$44.5 million
2018_11_16 AGM Presentation 2018
Prana invites investors unable to attend the Company’s Annual General Meeting to participate via teleconference.
PBT434 prevents alpha-synuclein aggregation, preserves neurons, reduces glial cell inclusions and slows motor dysfunction in an animal model of Multiple System Atrophy
Prana’s PBT434 prevents neuronal loss in a new model of neurodegeneration
Prana Biotechnology is pleased to announce the first cohort of volunteers in its Phase I clinical trial have been administered PBT434, an experimental drug under investigation for the treatment of Parkinsonian diseases.
1_Prana Biotechnology Investor Presentation_2018-0627 final
Prana Biotechnology is pleased to announce it has received ethics committee approval and has commenced recruitment for its Phase I Clinical trial evaluating the safety, tolerability and pharmacokinetics of the Company’s lead drug candidate, PBT434, in healthy volunteers.
Prana Biotechnology will be presenting at the China Healthcare Investment & Partnering Symposium on Saturday 17 March 2018 at 9.30am China Standard Time. Please access the webcast via the following link: http://wsw.com/webcast/brileyco20/pran/ The webcast will be archived for 90 days following the presentation.